FDA approves Trodelvy (sacituzumab govitecan-hziy) for treatment of adult patients with metastatic triple-negative breast cancer

Approval of this Trop-2-directed antibody and topoisomerase inhibitor drug conjugate is for use in patients who have received ≥2 prior therapies, and based on trial (n= 108) reporting overall response rate of 33.3%, with median duration of response of 7.7 months.


Biospace Inc.